Munich AI Startup Cellbyte Raises $2.75 Million Seed to Speed Drug Launches

Overview

• The round was led by Frontline Ventures with participation from Y Combinator, Pace Ventures, Saras Capital and Springboard Health Angels.
• Cellbyte’s platform centralizes clinical, pricing, regulatory and HTA data to automate market access and pricing workflows with real-time, natural‑language analysis.
• The company reports reaching six‑figure annual recurring revenue within weeks of launch and securing enterprise contracts that include Bayer.
• Funding will be used to triple headcount, scale engineering and expand customer operations across Europe and the United States.
• Founded in 2024 by Daniel Moreira, Felix Steinbrenner and Samuel Moreira, the startup aims to cut post‑approval delays that slow patient access to new therapies.